Parkside Financial Bank & Trust Boosts Stock Holdings in AbbVie Inc. $ABBV

Parkside Financial Bank & Trust boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 48.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,755 shares of the company’s stock after buying an additional 9,381 shares during the quarter. Parkside Financial Bank & Trust’s holdings in AbbVie were worth $5,337,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ABBV. Freemont Management S.A. raised its stake in AbbVie by 30.3% in the 2nd quarter. Freemont Management S.A. now owns 8,600 shares of the company’s stock valued at $1,596,000 after purchasing an additional 2,000 shares during the last quarter. Aviva PLC raised its position in shares of AbbVie by 8.0% in the second quarter. Aviva PLC now owns 1,322,515 shares of the company’s stock valued at $245,485,000 after buying an additional 98,463 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of AbbVie by 28.8% in the second quarter. Los Angeles Capital Management LLC now owns 2,020,005 shares of the company’s stock worth $374,953,000 after buying an additional 451,078 shares in the last quarter. AGF Management Ltd. boosted its position in AbbVie by 47.7% during the second quarter. AGF Management Ltd. now owns 1,133,774 shares of the company’s stock worth $210,451,000 after acquiring an additional 366,342 shares during the last quarter. Finally, AE Wealth Management LLC grew its stake in AbbVie by 6.9% during the 2nd quarter. AE Wealth Management LLC now owns 267,673 shares of the company’s stock valued at $49,686,000 after acquiring an additional 17,167 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ABBV shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Evercore ISI lifted their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Bank of America boosted their price target on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, Wall Street Zen upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $236.57.

Insider Buying and Selling at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.25% of the stock is owned by corporate insiders.

AbbVie Trading Down 0.1%

Shares of NYSE ABBV opened at $218.92 on Friday. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a 50-day moving average of $223.24 and a two-hundred day moving average of $202.30. The company has a market cap of $386.74 billion, a PE ratio of 104.25, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company posted $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s payout ratio is currently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.